Urology
Volume 75, Issue 5 , Pages 1138-1143 , May 2010

The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis

  • Steven C. Campbell

      Affiliations

    • Edward Hines Jr VA Hospital, Hines, Illinois
    • Corresponding Author InformationReprint requests: Steven C. Campbell, M.D., Ph.D., Section of Urologic Oncology, Glickman Urological and Kidney Institute, 9500 Euclid Ave, Desk A100, Cleveland, OH 44195
    • ,
  • Nirmala Bhoopalam

      Affiliations

    • Edward Hines Jr VA Hospital, Hines, Illinois
    • ,
  • Thomas E. Moritz

      Affiliations

    • Hines VA Cooperative Studies Program Coordinating Center, Hines, Illinois
    • ,
  • Mona Pandya

      Affiliations

    • Edward Hines Jr VA Hospital, Hines, Illinois
    • ,
  • Padmini Iyer

      Affiliations

    • VA Long Beach Health Care System, Long Beach, California
    • ,
  • Peter VanVeldhuizen

      Affiliations

    • Kansas City VA, Kansas City, Missouri
    • ,
  • Nancy K. Ellis

      Affiliations

    • Hines VA Cooperative Studies Program Coordinating Center, Hines, Illinois
    • ,
  • Lizy Thottapurathu

      Affiliations

    • Hines VA Cooperative Studies Program Coordinating Center, Hines, Illinois
    • ,
  • Harinder Garewal

      Affiliations

    • Southern Arizona VA Health Care System, Tucson, Arizona
    • ,
  • Stuart R. Warren

      Affiliations

    • VA Cooperative Studies Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico
    • ,
  • Nicholas Friedman

      Affiliations

    • Edward Hines Jr VA Hospital, Hines, Illinois
    • ,
  • Domenic J. Reda

      Affiliations

    • Hines VA Cooperative Studies Program Coordinating Center, Hines, Illinois

Received 31 August 2009 ,Accepted 21 November 2009.

References 

  1. Adib RS, Anderson JB, Ashken MH, et al. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–246
  2. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  3. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol. 2004;45:26–34
  4. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167:1953–1956
  5. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79:545–550
  6. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219–1222
  7. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002;60:79–86
  8. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–1728
  9. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007;177:17–24
  10. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol. 2008;179:414–423
  11. Shahinian VB, Kuo Y, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164
  12. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35
  13. Higano CS. Management of bone loss in men with prostate cancer. J Urol. 2003;170:S59–S64
  14. Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64:335–340
  15. Nguyen TV, Eisman JA, Kelly PJ, et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255–263
  16. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012
  17. Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol. 2009;182:2257–2264
  18. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–1042
  19. Wadhaw VK, Wetson R, Parr NJ, et al. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients requiring androgen deprivation therapy for prostate cancer. [abstract 1017] J Urol. 2007;177:336
  20. Casey R. The effect of zoledronic acid on bone density in men with prostate cancer undergoing continuous androgen deprivation therapy: a two year, perspective, randomized, multicenter study comparing zoledronic acid to no treatment. [abstract 1590] J Urol. 2006;177:512
  21. Ryan CW, Huo D, Demers LM, et al. Zometa US 05 investigators Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972–978
  22. Israeli RS, Rosenberg S, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5:271–277
  23. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–3846
  24. Smith M, Malkowicz S, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2007;179:152–155
  25. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008;26:4426–4434
  26. Morote J, Morin JP, Orsolo A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500–504
  27. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev. 1995;16:87–116
  28. Ryan CW, Huo D, Stallings JW, et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology. 2007;70:122–126
  29. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809
  30. Moyad MA. The potential benefits of dietary and/or supplemental calcium and vitamin D. Urol Oncol. 2003;21:384–398

 This investigator-initiated study was supported by a grant from Novartis Pharmaceutical Corporation, East Hanover, NJ.

 The protocol design, study conduct, results review, statistical analysis, and protocol monitoring were conducted independently by the Cooperative Studies Coordinating Center, Hines, IL. The study medication was provided by Novartis Pharmaceuticals Corporation and distributed by the Cooperative Studies Clinical Research Pharmacy Coordinating Center, Albuquerque, NM.

 Organizational members of the Zoledronic Acid Trial (The use of zoledronic acid in men on androgen deprivation therapy for prostate cancer with preexisting osteoporosis”) were as follows: Principal investigators (Grant and Protocol development), Steven C. Campbell and Nirmala Bhoopalam; Co-Principal investigator (Grant and Protocol development), H. Garewal; Site Investigators, Steven C. Campbell and N. Bhoopalam (Hines, IL.), P. VanVeldhuizen (Kansas City, MO), P. Iyer (Long Beach, CA), A. Arcenas (Washington, DC), C. Vera (Boston, MA), H Gareval (Tucson, AZ); Cooperative Studies Coordinating Center, Hines, IL (Design, management, monitoring, and analysis of the study), Domenic J. Reda, Thomas E. Moritz, Nancy K. Ellis, Lizy Thottapurathu, Mazen Abdellatif, Jan Motyka; DXA central review, Nicholas Friedman (Hines, IL); Cooperative Studies Clinical Research Pharmacy Coordinating Center (Albuquerque, NM) (distribution of study drug and placebo), Stuart Warren, Jolene Day; Clinical Coordinator, Regina Chorley (Hines, IL.); Site Coordinators, I. Makar (Hines, IL), K. Gomes (Kansas City, MO), C. Kaneshiro (Long Beach, CA); Executive Committee, N. Bhoopalam (Chair), S. Campbell, H. Garewal, N. Friedman, M. Terris, D. J. Reda, S. Warren, T. E. Moritz, R. Chorley, N. K. Ellis, L. Lacerna (Novartis representation); Data Monitoring Board, R. Adler (Chair), M. Gong, G. McCabe, M. Spaulding.

 Participating VA hospitals: Hines VA Medical center, Hines, IL; VA Long Beach Health Care System, Long Beach, CA; Kansas City VA, Kansas City, MO; Southern Arizona VA Health Care System, Tucson, AZ; Washington, DC VA Medical Center, Washington, DC; VA Boston Healthcare System, Jamaica Plain Division, Boston, MA.

PII: S0090-4295(10)00045-2

doi: 10.1016/j.urology.2009.11.083

Urology
Volume 75, Issue 5 , Pages 1138-1143 , May 2010

Article Tools